Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE - Free Report) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $95.00 price objective on the biopharmaceutical company's stock.

RARE has been the subject of several other reports. Piper Sandler increased their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, January 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. Royal Bank of Canada restated an "outperform" rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Canaccord Genuity Group restated a "buy" rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Finally, Wedbush restated a "neutral" rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $93.50.

Ultragenyx Pharmaceutical Trading Up 2.7 %

RARE stock traded up $1.13 on Friday, hitting $43.62. 818,127 shares of the company's stock traded hands, compared to its average volume of 904,711. Ultragenyx Pharmaceutical has a 1-year low of $37.02 and a 1-year high of $60.37. The stock has a market cap of $4.03 billion, a price-to-earnings ratio of -6.74 and a beta of 0.60. The stock has a fifty day moving average of $43.46 and a 200-day moving average of $49.59.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical will post -6.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 11,727 shares of the company's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 5.80% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $35,000. Human Investing LLC bought a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $42,000. True Wealth Design LLC bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $43,000. Finally, Values First Advisors Inc. bought a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $56,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.